{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T17:09:53Z","timestamp":1779210593795,"version":"3.51.4"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The aim of this study is to examine documented strategies, challenges, and lessons related to clinical trial site operations during pandemics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This review focused on seven major pandemics: COVID-19, HIV\/AIDS, Ebola, SARS, MERS, H1N1, and Zika. Searches were conducted using PubMed and Embase between September 2024 and February 2025, yielding 7572 unique records. After dual screening, 47 articles met inclusion criteria, with an additional 8 identified through citation searching, for a total of 55. Non-English articles were translated using Google Translate. Data were extracted and thematically analyzed through iterative familiarization, keyword identification, coding, and consensus discussion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 55 included articles, most originated from the European Region (61%) and the Americas (52%), with additional representation from Africa (19%), the Western Pacific (8%), Eastern Mediterranean (5%), and Southeast Asia (5%). Percentages exceed 100% because several studies reported across multiple regions. Study designs were predominantly descriptive (60%) with fewer randomized controlled trials (22%), observational (18%), and cohort studies (2%). COVID-19 accounted for the majority of articles (58%), followed by HIV\/AIDS (20%), Ebola (13%), H1N1 (2%), and Zika (4%); no eligible studies addressed SARS or MERS.<\/jats:p>\n                    <jats:p>Operational themes included policy (73%), resources (55%), networks (53%), infrastructure (47%), technology (45%), study design (31%), and communication (22%). Publications peaked during pandemic years, reflecting intensified research activity. Reported challenges included protocol\u2013practice misalignment, fragmented infrastructure, regulatory bottlenecks, and under-resourced sites. Reported practices included early site engagement in protocol development, streamlined ethics and contracting processes, investment in digital and decentralized infrastructure, and cross-trained staff. Gaps included limited use of adaptive trial designs and insufficient cross-national collaboration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinical trial sites implemented systemic operational changes to sustain research during pandemics. Key lessons include the need to strengthen infrastructure, workforce capacity, and institutional adaptability, and the need to address persistent global inequities. Institutionalizing early site engagement, adaptive designs, and equitable collaboration will be essential to enable timely and resilient clinical research responses in future pandemics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09677-5","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:04:10Z","timestamp":1775520250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Operational strategies among infectious disease clinical trial sites during pandemics: a scoping review"],"prefix":"10.1186","volume":"27","author":[{"given":"K. L.","family":"Trigg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. W.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,7]]},"reference":[{"key":"9677_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/J.JCLINEPI.2016.07.016","volume":"80","author":"M Briel","year":"2016","unstructured":"Briel M, Olu KK, von Elm E, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol. 2016;80:8\u201315. https:\/\/doi.org\/10.1016\/J.JCLINEPI.2016.07.016.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"9677_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13063-023-07414-W\/TABLES\/2","volume":"24","author":"A Lorenc","year":"2023","unstructured":"Lorenc A, Rooshenas L, Conefrey C, et al. Non-COVID-19 UK clinical trials and the COVID-19 pandemic: impact, challenges and possible solutions. Trials. 2023;24(1):1\u20138. https:\/\/doi.org\/10.1186\/S13063-023-07414-W\/TABLES\/2.","journal-title":"Trials"},{"issue":"1","key":"9677_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/JLB\/LSAA057","volume":"7","author":"H Fernandez Lynch","year":"2020","unstructured":"Fernandez Lynch H, Dickert NW, Zettler PJ, Joffe S, Largent EA. Regulatory flexibility for COVID-19 research. J Law Biosci. 2020;7(1):1\u201310. https:\/\/doi.org\/10.1093\/JLB\/LSAA057.","journal-title":"J Law Biosci"},{"key":"9677_CR4","unstructured":"Kloda JH, Somerville S. FDA\u2019s Expedited review process: the need for speed. Applied Clinical Trials. 2015. https:\/\/www.appliedclinicaltrialsonline.com\/view\/fda-s-expedited-review-process-need-speedAccessed 9 Nov 2023."},{"key":"9677_CR5","unstructured":"U.S. Department of Veterans Affairs. How long before a drug is approved by the FDA? U.S. Department of Veterans Affairs. 2023. https:\/\/www.hiv.va.gov\/patient\/clinical-trials\/drug-approval-process.asp Accessed 9 Nov 2023."},{"key":"9677_CR6","unstructured":"Johns Hopkins Medicine. Improving the efficiency of clinical trials. Neurologic. 2020. https:\/\/www.hopkinsmedicine.org\/news\/articles\/2020\/01\/improving-the-efficiency-of-clinical-trialsAccessed 9 Nov 2023."},{"issue":"1","key":"9677_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.4103\/JFMPC.JFMPC_578_19","volume":"9","author":"A Batta","year":"2020","unstructured":"Batta A, Kalra B, Khirasaria R. Trends in FDA drug approvals over last 2 decades: an observational study. J Family Med Prim Care. 2020;9(1):105. https:\/\/doi.org\/10.4103\/JFMPC.JFMPC_578_19.","journal-title":"J Family Med Prim Care"},{"issue":"1","key":"9677_CR8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1089\/BLR.2015.9999","volume":"34","author":"EE Kepplinger","year":"2015","unstructured":"Kepplinger EE. FDA\u2019s expedited approval mechanisms for new drug products. Biotechnol Law Rep. 2015;34(1):15. https:\/\/doi.org\/10.1089\/BLR.2015.9999.","journal-title":"Biotechnol Law Rep"},{"issue":"11","key":"9677_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/BMJGH-2023-013480","volume":"8","author":"M Mercuri","year":"2023","unstructured":"Mercuri M, Hackett K, Upshur R, Emerson CI. Expediting approval for medical countermeasures to address high burden disease: an ethical justification to move beyond emergency use authorisation. BMJ Glob Health. 2023;8(11):e013480. https:\/\/doi.org\/10.1136\/BMJGH-2023-013480.","journal-title":"BMJ Glob Health"},{"key":"9677_CR10","unstructured":"Jones R. Addressing The Clinical Trial Industry\u2019s Participation Problem: What Role Can Academic Medical Centers Play? Forbes. https:\/\/www.forbes.com\/sites\/forbestechcouncil\/2021\/08\/18\/addressing-the-clinical-trial-industrys-participation-problem-what-role-can-academic-medical-centers-play\/?sh=582837483af9. Accessed 9 Nov 2023."},{"key":"9677_CR11","unstructured":"Rudoy J, Baggot D, Yu Z. The future of academic medical centers. Oliver Wyman. Published online April 2021. https:\/\/www.oliverwyman.com\/our-expertise\/perspectives\/health\/2021\/apr\/the-future-of-academic-medical-centers.html Accessed 9 Nov 2023."},{"issue":"6","key":"9677_CR12","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/S40271-020-00460-5","volume":"13","author":"M Parry","year":"2020","unstructured":"Parry M, Bj\u00f8rnnes AK, Toupin-April K, et al. Patient engagement partnerships in clinical trials: development of patient partner and investigator decision aids. Patient. 2020;13(6):745. https:\/\/doi.org\/10.1007\/S40271-020-00460-5.","journal-title":"Patient"},{"key":"9677_CR13","unstructured":"Clinical Trials Transformation Initiative. Engaging All Stakeholders in Clinical Trial Design. Preprint posted online 2023. https:\/\/ctti-clinicaltrials.org\/our-work\/quality\/engaging-stakeholders-in-trial-design\/ Accessed 9 Nov 2023."},{"issue":"17","key":"9677_CR14","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1056\/NEJMSB021319","volume":"347","author":"HI Moses","year":"2002","unstructured":"Moses HI, Braunwald E, Martin JB, Thier SO. Collaborating with industry\u2014choices for the academic medical center. N Engl J Med. 2002;347(17):1371\u20135. https:\/\/doi.org\/10.1056\/NEJMSB021319.","journal-title":"N Engl J Med"},{"issue":"21","key":"9677_CR15","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMSA044115","volume":"352","author":"MM Mello","year":"2005","unstructured":"Mello MM, Clarridge BR, Studdert DM. Academic medical centers\u2019 standards for clinical-trial agreements with industry. N Engl J Med. 2005;352(21):2202\u201310. https:\/\/doi.org\/10.1056\/NEJMSA044115.","journal-title":"N Engl J Med"},{"key":"9677_CR16","unstructured":"Impact of COVID-19 on clinical trial operations and regulatory interactions. https:\/\/globalforum.diaglobal.org\/issue\/december-2020\/impact-of-covid-19-on-clinical-trial-operations-and-regulatory-interactions\/. Accessed 9 Nov 2023."},{"issue":"1","key":"9677_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/XEB.0000000000000277","volume":"19","author":"MDJ Peters","year":"2021","unstructured":"Peters MDJ, Marnie C, Tricco AC, et al. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Implement. 2021;19(1):3\u201310. https:\/\/doi.org\/10.1097\/XEB.0000000000000277.","journal-title":"JBI Evid Implement"},{"issue":"7","key":"9677_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850\/SUPPL_FILE\/M18-0850_SUPPLEMENT.PDF","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373. https:\/\/doi.org\/10.7326\/M18-0850\/SUPPL_FILE\/M18-0850_SUPPLEMENT.PDF.","journal-title":"Ann Intern Med"},{"key":"9677_CR19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2024638","author":"HC Lane","year":"2021","unstructured":"Lane HC, Fauci AS. Research in the context of a pandemic. n engl j med. 2021. https:\/\/doi.org\/10.1056\/NEJMe2024638.","journal-title":"n engl j med"},{"key":"9677_CR20","first-page":"728","volume":"79","author":"C Wheeler","year":"2001","unstructured":"Wheeler C, Berkley S. Initial lessons from public-private partnerships in drug and vaccine development. Bull World Health Organ. 2001;79:728\u201334.","journal-title":"Bull World Health Organ."},{"key":"9677_CR21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S1473-3099(03)00551-6","volume":"3","author":"P Das","year":"2003","unstructured":"Das P. Tim Tucker-director of the South African AIDS vaccine initiative. Lancet Infect Dis. 2003;3:173\u20135. https:\/\/doi.org\/10.1016\/S1473-3099(03)00551-6.","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"9677_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1177\/17407745211049829","volume":"19","author":"DD Murray","year":"2022","unstructured":"Murray DD, Babiker AG, Baker JV, et al. Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO\/ACTIV-3) HHS Public Access. Clin Trials. 2022;19(1):52\u201361. https:\/\/doi.org\/10.1177\/17407745211049829.","journal-title":"Clin Trials"},{"issue":"12","key":"9677_CR23","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1093\/CID\/CIAD418","volume":"77","author":"S Narayanasamy","year":"2023","unstructured":"Narayanasamy S, Curtis LH, Hernandez AF, et al. Lessons from COVID-19 for pandemic preparedness: proceedings from a multistakeholder think tank. Clin Infect Dis. 2023;77(12):1635\u201343. https:\/\/doi.org\/10.1093\/CID\/CIAD418.","journal-title":"Clin Infect Dis"},{"key":"9677_CR24","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2017.1398485","author":"A Wilder-Smith","year":"2017","unstructured":"Wilder-Smith A, Preet R, Renhorn KE, et al. ZikaPLAN: Zika Preparedness Latin American Network. Glob Health Action. 2017. https:\/\/doi.org\/10.1080\/16549716.2017.1398485.","journal-title":"Glob Health Action"},{"issue":"1","key":"9677_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1089\/HS.2018.0100","volume":"17","author":"A Vasa","year":"2019","unstructured":"Vasa A, Madad S, Larson LA, et al. A novel approach to infectious disease preparedness: incorporating investigational therapeutics and research objectives into full-scale exercises. Health Secur. 2019;17(1):54\u201361. https:\/\/doi.org\/10.1089\/HS.2018.0100.","journal-title":"Health Secur"},{"issue":"1","key":"9677_CR26","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2022.51974","volume":"6","author":"AJ Mena Lora","year":"2023","unstructured":"Mena Lora AJ, Long JE, Huang Y, et al. Rapid development of an integrated network infrastructure to conduct phase 3 COVID-19 vaccine trials. JAMA Netw Open. 2023;6(1):e2251974. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2022.51974.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"9677_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13063-023-07862-4\/FIGURES\/3","volume":"25","author":"S Baos","year":"2024","unstructured":"Baos S, Todd R, Thirard R, et al. Delivering COVID-19 vaccine trials at speed: the implementation of a phase IV UK multi-centre randomised controlled trial to determine safety and immunogenicity of COVID-19 vaccines co-administered with seasonal influenza vaccines (ComFluCOV). Trials. 2024;25(1):1\u201313. https:\/\/doi.org\/10.1186\/S13063-023-07862-4\/FIGURES\/3.","journal-title":"Trials"},{"issue":"51","key":"9677_CR28","doi-asserted-by":"publisher","first-page":"7587","DOI":"10.1016\/J.VACCINE.2023.11.030","volume":"41","author":"Y Larivi\u00e8re","year":"2023","unstructured":"Larivi\u00e8re Y, Matuvanga TZ, Lemey G, et al. Conducting an Ebola vaccine trial in a remote area of the Democratic Republic of the Congo: challenges, mitigations, and lessons learned. Vaccine. 2023;41(51):7587\u201397. https:\/\/doi.org\/10.1016\/J.VACCINE.2023.11.030.","journal-title":"Vaccine"},{"key":"9677_CR29","doi-asserted-by":"publisher","DOI":"10.1017\/CTS.2021.836","author":"M Subramain","year":"2021","unstructured":"Subramain M, Wangui-Verry JM, Sprenger KJ, Comellas AP, Barlow PB. Impact of COVID-19 on clinical research units (CRUs). J Cardiothorac Vasc Anesth. 2021. https:\/\/doi.org\/10.1017\/CTS.2021.836.","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"9677_CR30","doi-asserted-by":"publisher","DOI":"10.1017\/CTS.2022.484","author":"JA Croker","year":"2022","unstructured":"Croker JA, Valenti S, Baus HA, et al. Leveraging CTSA hubs for rapid, large-scale, high-impact research: A case study during a global public health emergency. Journal of Clinical and Translational Science. 2022. https:\/\/doi.org\/10.1017\/CTS.2022.484.","journal-title":"Journal of Clinical and Translational Science"},{"key":"9677_CR31","doi-asserted-by":"publisher","DOI":"10.1017\/CTS.2021.15","author":"M Gravelin","year":"2021","unstructured":"Gravelin M, Wright J, Holbein MEB, et al. Role of CTSA institutes and academic medical centers in facilitating preapproval access to investigational agents and devices during the COVID-19 pandemic. J Clin Transl Sci. 2021. https:\/\/doi.org\/10.1017\/CTS.2021.15.","journal-title":"J Clin Transl Sci"},{"issue":"4","key":"9677_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/S13149-016-0527-9\/METRICS","volume":"109","author":"D Malvy","year":"2016","unstructured":"Malvy D. Produire de la science en situation de crise. Les traitements m\u00e9dicamenteux sp\u00e9cifiques de la maladie \u00e0 virus Ebola en 2016\u202f: le\u00e7ons et perspectives. Bull Soc Pathol Exot. 2016;109(4):262\u201371. https:\/\/doi.org\/10.1007\/S13149-016-0527-9\/METRICS.","journal-title":"Bull Soc Pathol Exot"},{"key":"9677_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCT.2023.107267","author":"C Fougerou-Leurent","year":"2023","unstructured":"Fougerou-Leurent C, Delmas C, Saillard J, et al. Ensuring quality control in a COVID-19 clinical trial during the pandemic: The experience of the Inserm C20-15 DisCoVeRy study. Contemp Clin Trials. 2023. https:\/\/doi.org\/10.1016\/J.CCT.2023.107267.","journal-title":"Contemp Clin Trials"},{"key":"9677_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3233\/SHTI230071","volume":"302","author":"D Krefting","year":"2023","unstructured":"Krefting D, Anton G, Chaplinskaya-Sobol I, et al. The importance of being FAIR and FAST \u2013 The Clinical Epidemiology and Study Platform of the German Network University Medicine (NUKLEUS). Stud Health Technol Inform. 2023;302:93\u20137. https:\/\/doi.org\/10.3233\/SHTI230071.","journal-title":"Stud Health Technol Inform"},{"issue":"3","key":"9677_CR35","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1177\/1740774520988298\/ASSET\/IMAGES\/LARGE\/10.1177_1740774520988298-FIG5.JPEG","volume":"18","author":"H Hedlin","year":"2021","unstructured":"Hedlin H, Garcia A, Weng Y, et al. Clinical trials in a COVID-19 pandemic: shared infrastructure for continuous learning in a rapidly changing landscape. Clin Trials. 2021;18(3):324\u201334. https:\/\/doi.org\/10.1177\/1740774520988298\/ASSET\/IMAGES\/LARGE\/10.1177_1740774520988298-FIG5.JPEG.","journal-title":"Clin Trials"},{"issue":"1","key":"9677_CR36","doi-asserted-by":"publisher","DOI":"10.1017\/CTS.2021.866","volume":"6","author":"ME Palm","year":"2022","unstructured":"Palm ME, Lindsell CJ, Selker HP, et al. Sharing data among clinical trials of therapeutics in COVID-19: Barriers and facilitators to collaborating in a crisis. J Clin Transl Sci. 2022;6(1):e52. https:\/\/doi.org\/10.1017\/CTS.2021.866.","journal-title":"J Clin Transl Sci"},{"issue":"1","key":"9677_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13063-020-04711-6\/METRICS","volume":"21","author":"EJ Mitchell","year":"2020","unstructured":"Mitchell EJ, Ahmed K, Breeman S, et al. It is unprecedented: trial management during the COVID-19 pandemic and beyond. Trials. 2020;21(1):1\u20137. https:\/\/doi.org\/10.1186\/S13063-020-04711-6\/METRICS.","journal-title":"Trials"},{"issue":"1","key":"9677_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13063-020-04997-6\/FIGURES\/4","volume":"22","author":"DT Huang","year":"2021","unstructured":"Huang DT, McVerry BJ, Horvat C, et al. Implementation of the randomized embedded multifactorial adaptive platform for COVID-19 (REMAP-COVID) trial in a US health system\u2014lessons learned and recommendations. Trials. 2021;22(1):1\u201311. https:\/\/doi.org\/10.1186\/S13063-020-04997-6\/FIGURES\/4.","journal-title":"Trials"},{"key":"9677_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCT.2021.106660","author":"AS Bangdiwala","year":"2022","unstructured":"Bangdiwala AS, Boulware DR. Technical procedures and REDCap tools for internet-based clinical trials. Contemp Clin Trials. 2022. https:\/\/doi.org\/10.1016\/J.CCT.2021.106660.","journal-title":"Contemp Clin Trials"},{"key":"9677_CR40","unstructured":"Ruiz-Palacios G, Guerrero ML, Galindo-Fraga A, et al.\u00a0\u201cLa Red: The formation of an emerging infectious diseases clinical research network in Mexico.\u201d\u00a0Society for Clinical Trials Annual Meeting, Vancouver, 2011."},{"key":"9677_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/JAMIAOPEN\/OOAE023","author":"NH Goldhaber","year":"2024","unstructured":"Goldhaber NH, Jacobs MB, Laurent LC, et al. Integrating clinical research into electronic health record workflows to support a learning health system. JAMIA Open. 2024. https:\/\/doi.org\/10.1093\/JAMIAOPEN\/OOAE023.","journal-title":"JAMIA Open"},{"key":"9677_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/leader-2021-000566","volume":"0","author":"D Coe","year":"2022","unstructured":"Coe D, Dorgan S, Smith J, Wroe C. Identification of the ideal recruitment situation in pandemic research: learning from the RECOVERY trial in Northern England: a qualitative study. BMJ Leader. 2022;0:1\u20139. https:\/\/doi.org\/10.1136\/leader-2021-000566.","journal-title":"BMJ Leader"},{"issue":"4","key":"9677_CR43","first-page":"717","volume":"62","author":"R Sweeney","year":"2000","unstructured":"Sweeney R, Lapp T. NIAID will fund HIV vaccine trials network. Am Fam Physician. 2000;62(4):717\u20138.","journal-title":"Am Fam Physician."},{"issue":"9426","key":"9677_CR44","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/s0140-6736(04)16488-x","volume":"363","author":"R Walgate","year":"2004","unstructured":"Walgate R. G8 support for vaccine initiative draws mixed reactions. Lancet. 2004;363(9426):2055. https:\/\/doi.org\/10.1016\/s0140-6736(04)16488-x.","journal-title":"Lancet"},{"issue":"2","key":"9677_CR45","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/1740774512470765","volume":"10","author":"M Hanna","year":"2013","unstructured":"Hanna M, Minga A, Fao P, et al. Development of a checklist of quality indicators for clinical trials in resource-limited countries: the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) experience. Clin Trials. 2013;10(2):300\u201318. https:\/\/doi.org\/10.1177\/1740774512470765.","journal-title":"Clin Trials"},{"issue":"1","key":"9677_CR46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/J.THERAP.2021.12.008","volume":"77","author":"D Deplanque","year":"2022","unstructured":"Deplanque D, Cviklinski S, Bardou M, et al. Health crisis: what opportunities for clinical drug research? Therapies. 2022;77(1):59\u201367. https:\/\/doi.org\/10.1016\/J.THERAP.2021.12.008.","journal-title":"Therapies"},{"issue":"2","key":"9677_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1353\/nas.2004.0020","volume":"7","author":"E Sanders","year":"2000","unstructured":"Sanders E, Woldemichael T, Geyid A. Development of research capability in Ethiopia: the Ethio-Netherlands HIV\/AIDS research project (ENARP), 1994-2002. Northeast Afr Stud. 2000;7(2):101\u201317. A\u200bcessed 5 Feb 2025.","journal-title":"Northeast Afr Stud"},{"issue":"1","key":"9677_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1478-4505-11-18","volume":"11","author":"L Paina","year":"2013","unstructured":"Paina L, Ssengooba F, Waswa D, M\u2019Imunya JM, Bennett S. How does investment in research training affect the development of research networks and collaborations? Health Res Policy Syst. 2013;11(1):1\u201313. https:\/\/doi.org\/10.1186\/1478-4505-11-18.","journal-title":"Health Res Policy Syst"},{"issue":"1","key":"9677_CR49","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/1740774515621037","volume":"13","author":"SB Kennedy","year":"2016","unstructured":"Kennedy SB, Neaton JD, Lane HC, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges. Clin Trials. 2016;13(1):49\u201356. https:\/\/doi.org\/10.1177\/1740774515621037.","journal-title":"Clin Trials"},{"issue":"1","key":"9677_CR50","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/1740774515619897","volume":"13","author":"NM Thielman","year":"2016","unstructured":"Thielman NM, Cunningham CK, Woods C, Petzold E, Sprenz M, Russell J. Ebola clinical trials: five lessons learned and a way forward. Clin Trials. 2016;13(1):83\u20136. https:\/\/doi.org\/10.1177\/1740774515619897.","journal-title":"Clin Trials"},{"issue":"1","key":"9677_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/4669","volume":"5","author":"A Dove","year":"1999","unstructured":"Dove A. IAVI advances AIDS vaccine research\u2026. Nat Med. 1999;5(1):5. https:\/\/doi.org\/10.1038\/4669.","journal-title":"Nat Med"},{"issue":"4","key":"9677_CR52","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1097\/CCM.0B013E318275D061","volume":"41","author":"KEA Burns","year":"2013","unstructured":"Burns KEA, Rizvi L, Tan W, Marshall JC, Pope K. Participation of ICUs in critical care pandemic research: a province wide, cross-sectional survey. Crit Care Med. 2013;41(4):1009\u201316. https:\/\/doi.org\/10.1097\/CCM.0B013E318275D061.","journal-title":"Crit Care Med"},{"issue":"Suppl 3","key":"9677_CR53","doi-asserted-by":"publisher","first-page":"A38","DOI":"10.1136\/ARCHDISCHILD-2021-GOSH.103","volume":"106","author":"H Ashton","year":"2021","unstructured":"Ashton H, Cooper L. 103\u2005Development of the paediatric research advanced nurse practitioner (ANP) role during a global pandemic. Arch Dis Child. 2021;106(Suppl 3):A38\u20139. https:\/\/doi.org\/10.1136\/ARCHDISCHILD-2021-GOSH.103.","journal-title":"Arch Dis Child"},{"issue":"3","key":"9677_CR54","doi-asserted-by":"publisher","DOI":"10.1177\/17407745231154215","volume":"20","author":"K Thriemer","year":"2023","unstructured":"Thriemer K, Degaga TS, Alam MS, et al. Adapting international clinical trials during COVID-19 and beyond. Clin Trials. 2023;20(3):237. https:\/\/doi.org\/10.1177\/17407745231154215.","journal-title":"Clin Trials"},{"key":"9677_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/J.CONCTC.2021.100833","volume":"24","author":"J Kagan","year":"2021","unstructured":"Kagan J, Lassa J, Zuckerman J, et al. Strategy management in collaborative clinical research partnerships. Contemp Clin Trials Commun. 2021;24:100833. https:\/\/doi.org\/10.1016\/J.CONCTC.2021.100833.","journal-title":"Contemp Clin Trials Commun"},{"key":"9677_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/J.CONCTC.2023.101106","volume":"33","author":"J McClure","year":"2023","unstructured":"McClure J, Asghar A, Krajec A, et al. Clinical trial facilitators: a novel approach to support the execution of clinical research at the study site level. Contemp Clin Trials Commun. 2023;33:101106. https:\/\/doi.org\/10.1016\/J.CONCTC.2023.101106.","journal-title":"Contemp Clin Trials Commun"},{"issue":"2","key":"9677_CR57","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/S0264-410X(03)00212-3","volume":"21","author":"D Medaglini","year":"2003","unstructured":"Medaglini D, Hoeveler A. The European research effort for HIV\/AIDS, malaria and tuberculosis. Vaccine. 2003;21(2):S116\u201320. https:\/\/doi.org\/10.1016\/S0264-410X(03)00212-3.","journal-title":"Vaccine"},{"issue":"31","key":"9677_CR58","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1016\/J.VACCINE.2022.05.022","volume":"40","author":"J Salmanton-Garc\u00eda","year":"2022","unstructured":"Salmanton-Garc\u00eda J, Stewart FA, Heringer S, et al. VACCELERATE volunteer registry: a European study participant database to facilitate clinical trial enrolment. Vaccine. 2022;40(31):4090\u20137. https:\/\/doi.org\/10.1016\/J.VACCINE.2022.05.022.","journal-title":"Vaccine"},{"issue":"1","key":"9677_CR59","doi-asserted-by":"publisher","DOI":"10.1017\/CTS.2023.644","volume":"7","author":"Group TAC 19 TI and V (ACTIV) 6 S","year":"2023","unstructured":"Group TAC 19 TI and V (ACTIV) 6 S. ACTIV-6: Operationalizing a decentralized, outpatient randomized platform trial to evaluate efficacy of repurposed medicines for COVID-19. J Clin Transl Sci. 2023;7(1):e221. https:\/\/doi.org\/10.1017\/CTS.2023.644.","journal-title":"J Clin Transl Sci"},{"issue":"4","key":"9677_CR60","doi-asserted-by":"publisher","DOI":"10.3390\/V13040687","volume":"13","author":"MdasGC Alecrim","year":"2021","unstructured":"Alecrim MdasGC, de Amorim MMR, de Ara\u00fajo TVB, et al. Zika Brazilian cohorts (ZBC) consortium: protocol for an individual participant data meta-analysis of congenital zika syndrome after maternal exposure during pregnancy. Viruses. 2021;13(4):687. https:\/\/doi.org\/10.3390\/V13040687.","journal-title":"Viruses"},{"key":"9677_CR61","doi-asserted-by":"publisher","DOI":"10.2196\/35032","author":"J Brown","year":"2022","unstructured":"Brown J, Bhatnagar M, Gordon H, Goodner J, Cobb JP, Lutrick K. An electronic data capture tool for data collection during public health emergencies: development and usability study. JMIR Hum Factors. 2022. https:\/\/doi.org\/10.2196\/35032.","journal-title":"JMIR Hum Factors"},{"key":"9677_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/J.TACC.2021.03.010","volume":"38","author":"H Garg","year":"2021","unstructured":"Garg H, Khanna P. Consent in covid: a researcher\u2019s dilemma. Trends Anaesth Crit Care. 2021;38:10. https:\/\/doi.org\/10.1016\/J.TACC.2021.03.010.","journal-title":"Trends Anaesth Crit Care"},{"issue":"1","key":"9677_CR63","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cct.2008.09.001","volume":"30","author":"C Van Der Horst","year":"2009","unstructured":"Van Der Horst C, Chasela C, Ahmed Y, et al. Modifications of a large HIV prevention clinical trial to fit changing realities: a case study of the Breastfeeding, Antiretroviral, and Nutrition (BAN) Protocol in Lilongwe, Malawi. Contemp Clin Trials. 2009;30(1):24\u201333. https:\/\/doi.org\/10.1016\/j.cct.2008.09.001.","journal-title":"Contemp Clin Trials"},{"key":"9677_CR64","doi-asserted-by":"publisher","first-page":"A22","DOI":"10.1136\/BMJOQ-2021-IHI.18","volume":"10","author":"MA Dolansky","year":"2021","unstructured":"Dolansky MA, Pohnert A. The intersection of quality improvement and implementation science: a case study. BMJ Open Quality. 2021;10:A22\u20134. https:\/\/doi.org\/10.1136\/BMJOQ-2021-IHI.18. (British Medical Journal Publishing Group).","journal-title":"BMJ Open Quality"},{"key":"9677_CR65","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005545","author":"S Carazo Perez","year":"2017","unstructured":"Carazo Perez S, Folkesson E, Anglaret X, et al. Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: a case study in Guinea, West Africa. PLoS Negl Trop Dis. 2017. https:\/\/doi.org\/10.1371\/journal.pntd.0005545.","journal-title":"PLoS Negl Trop Dis"},{"key":"9677_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/J.CONCTC.2021.100804","author":"P Woods","year":"2021","unstructured":"Woods P, Flynn M, Monach P, et al. Implementation of documented and written informed consent for clinical trials of communicable diseases: lessons learned, barriers, solutions, future directions identified during the conduct of a COVID-19 clinical trial. Contemp Clin Trials Commun. 2021. https:\/\/doi.org\/10.1016\/J.CONCTC.2021.100804.","journal-title":"Contemp Clin Trials Commun"},{"key":"9677_CR67","doi-asserted-by":"publisher","DOI":"10.1017\/CTS.2021.777","author":"YR Sedhai","year":"2021","unstructured":"Sedhai YR, Sears M, Vecchi\u00e8 A, et al. Clinical trial enrollment at a rural satellite hospital during COVID-19 pandemic. Journal of Clinical and Translational Science. 2021. https:\/\/doi.org\/10.1017\/CTS.2021.777.","journal-title":"Journal of Clinical and Translational Science"},{"issue":"1","key":"9677_CR68","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1089\/tmr.2021.0010","volume":"2","author":"GF Gloston","year":"2021","unstructured":"Gloston GF, Day GA, Touchett HN, et al. Pivoting to video telehealth for delivery of HIV care during COVID-19: a brief report. Telemed Rep. 2021;2(1):205\u201310. https:\/\/doi.org\/10.1089\/tmr.2021.0010.","journal-title":"Telemed Rep"},{"issue":"Suppl E","key":"9677_CR69","doi-asserted-by":"publisher","first-page":"E161","DOI":"10.1093\/eurheartj\/suab112","volume":"23","author":"L Tavazzi","year":"2021","unstructured":"Tavazzi L. Clinical research methodology process: what is changing with COVID-19? Eur Heart J Suppl. 2021;23(Suppl E):E161\u20137. https:\/\/doi.org\/10.1093\/eurheartj\/suab112.","journal-title":"Eur Heart J Suppl"},{"key":"9677_CR70","doi-asserted-by":"publisher","DOI":"10.1016\/J.CCT.2021.106402","volume":"105","author":"A Mennecier","year":"2021","unstructured":"Mennecier A, Kankasa C, Fao P, et al. Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 promise-EPI study in Zambia and Burkina Faso. Contemp Clin Trials. 2021;105:106402. https:\/\/doi.org\/10.1016\/J.CCT.2021.106402.","journal-title":"Contemp Clin Trials"},{"key":"9677_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-005726","volume":"6","author":"G Lemey","year":"2021","unstructured":"Lemey G, Larivi\u00e8re Y, Zola TM, et al. Algorithm for the support of non-related (serious) adverse events in an Ebola vaccine trial in the Democratic Republic of the Congo. BMJ Glob Health. 2021;6:5726. https:\/\/doi.org\/10.1136\/bmjgh-2021-005726.","journal-title":"BMJ Glob Health"},{"issue":"4","key":"9677_CR72","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1513\/ANNALSATS.202008-940OC","volume":"18","author":"SM Brown","year":"2021","unstructured":"Brown SM, Peltan I, Kumar N, et al. Hydroxychloroquine versus azithromycin for hospitalized patients with COVID-19: results of a randomized, active comparator trial. Ann Am Thorac Soc. 2021;18(4):590\u20137. https:\/\/doi.org\/10.1513\/ANNALSATS.202008-940OC.","journal-title":"Ann Am Thorac Soc"},{"key":"9677_CR73","doi-asserted-by":"publisher","DOI":"10.1080\/16549716.2020.1829829","author":"J Kitonsa","year":"2020","unstructured":"Kitonsa J, Ggayi AB, Anywaine Z, et al. Implementation of accelerated research: strategies for implementation as applied in a phase 1 Ad26.ZEBOV, MVA-BN-Filo two-dose Ebola vaccine clinical trial in Uganda. Glob Health Action. 2020. https:\/\/doi.org\/10.1080\/16549716.2020.1829829.","journal-title":"Glob Health Action"},{"issue":"7","key":"9677_CR74","doi-asserted-by":"publisher","DOI":"10.1001\/JAMANETWORKOPEN.2024.20458","volume":"7","author":"D Cook","year":"2024","unstructured":"Cook D, Taneja S, Krewulak K, et al. Barriers, solutions, and opportunities for adapting critical care clinical trials in the COVID-19 pandemic. JAMA Netw Open. 2024;7(7):e2420458. https:\/\/doi.org\/10.1001\/JAMANETWORKOPEN.2024.20458.","journal-title":"JAMA Netw Open"},{"key":"9677_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2017-018320","author":"LE Bothwell","year":"2018","unstructured":"Bothwell LE, Avorn J, Khan NF, Kesselheim AS. Adaptive design clinical trials: a review of the literature and ClinicalTrials.gov. BMJ Open. 2018. https:\/\/doi.org\/10.1136\/BMJOPEN-2017-018320.","journal-title":"BMJ Open"},{"issue":"10","key":"9677_CR76","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.36470","volume":"6","author":"PA Harris","year":"2023","unstructured":"Harris PA, Dunsmore SE, Atkinson JC, et al. Leveraging the expertise of the CTSA program to increase the impact and efficiency of clinical trials. JAMA Netw Open. 2023;6(10):e2336470. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.36470.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"9677_CR77","doi-asserted-by":"publisher","DOI":"10.1136\/BMJOPEN-2022-062169","volume":"12","author":"F Anschau","year":"2022","unstructured":"Anschau F, Aredes NDA, Reveiz L, et al. Cohort study protocol of the Brazilian collaborative research network on COVID-19: strengthening WHO global data. BMJ Open. 2022;12(11):e062169. https:\/\/doi.org\/10.1136\/BMJOPEN-2022-062169.","journal-title":"BMJ Open"},{"issue":"9","key":"9677_CR78","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1093\/JAC\/DKAB190","volume":"76","author":"F Lemaitre","year":"2021","unstructured":"Lemaitre F, Locher C, Verdier MC, Naudet F. Clinical trials during pandemics and beyond: time for a more efficient pharmacological strategy. J Antimicrob Chemother. 2021;76(9):2234\u20136. https:\/\/doi.org\/10.1093\/JAC\/DKAB190.","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"9677_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00263-2","volume":"21","author":"R Dal-R\u00e9","year":"2021","unstructured":"Dal-R\u00e9 R, Bekker LG, Gluud C, et al. Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities. Lancet Infect Dis. 2021;21(11):e342. https:\/\/doi.org\/10.1016\/S1473-3099(21)00263-2.","journal-title":"Lancet Infect Dis"},{"key":"9677_CR80","doi-asserted-by":"publisher","first-page":"78137","DOI":"10.1136\/bmjopen-2023-078137","volume":"14","author":"N Sch\u00f6bi","year":"2024","unstructured":"Sch\u00f6bi N, Sanchez C, Welzel T, et al. Swissped-RECOVERY: masked independent adjudication for the interpretation of non-randomised treatment in a two-arm open-label randomised controlled trial (methylprednisolone vs immunoglobulins) in Paediatric Inflammatory Multisystem Syndrome Temporally As. BMJ Open. 2024;14:78137. https:\/\/doi.org\/10.1136\/bmjopen-2023-078137.","journal-title":"BMJ Open"},{"key":"9677_CR81","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcjq.2021.10.002","volume":"48","author":"L Shen","year":"2022","unstructured":"Shen L, Levie A, Singh H, Murray K, Desai S. Harnessing event report data to identify diagnostic error during the COVID-19 pandemic. The Joint Commission Journal on Quality and Patient Safety. 2022;48:71\u201380. https:\/\/doi.org\/10.1016\/j.jcjq.2021.10.002.","journal-title":"The Joint Commission Journal on Quality and Patient Safety"},{"key":"9677_CR82","unstructured":"Henry Ford Health System on their Clinical Trial Reorganization. May 27, 2024. https:\/\/theconferenceforum.org\/editorial\/henry-ford-health-system-on-their-clinical-trial-reorganization. Accessed 22 Sept 2024."},{"key":"9677_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/S13690-022-00999-9","author":"C Grenier","year":"2022","unstructured":"Grenier C, Loniewski M, Plazy M, et al. Implementing an outpatient clinical trial on COVID-19 treatment in an emergency epidemic context: a mixed methods study among operational and research stakeholders within the Coverage trial, Bordeaux (France). Archives of Public Health. 2022. https:\/\/doi.org\/10.1186\/S13690-022-00999-9.","journal-title":"Archives of Public Health"},{"key":"9677_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-0950-8","volume":"15","author":"OM Folayan","year":"2015","unstructured":"Folayan OM, Brown B, Haire B, Yakubu A, Peterson K, Tegli J. Stakeholders\u2019 engagement with Ebola therapy research in resource limited settings. BMC Infect Dis. 2015;15:242. https:\/\/doi.org\/10.1186\/s12879-015-0950-8.","journal-title":"BMC Infect Dis"},{"key":"9677_CR85","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/J.CONCTC.2016.06.008","volume":"4","author":"J Doe-Anderson","year":"2016","unstructured":"Doe-Anderson J, Baseler B, Driscoll P, et al. Beating the odds: successful establishment of a Phase II\/III clinical research trial in resource-poor Liberia during the largest-ever Ebola outbreak. Contemp Clin Trials Commun. 2016;4:68\u201373. https:\/\/doi.org\/10.1016\/J.CONCTC.2016.06.008.","journal-title":"Contemp Clin Trials Commun"},{"key":"9677_CR86","doi-asserted-by":"publisher","DOI":"10.1017\/cts.2021.852","author":"LA Musshafen","year":"2021","unstructured":"Musshafen LA, Poger JM, Simmons WR, et al. Strengthening the clinical research workforce through a competency-based orientation program: Process outcomes and lessons learned across three academic health institutions. Journal of Clinical and Translational Science. 2021. https:\/\/doi.org\/10.1017\/cts.2021.852.","journal-title":"Journal of Clinical and Translational Science"},{"key":"9677_CR87","doi-asserted-by":"publisher","DOI":"10.1017\/CTS.2022.423","author":"RC Shah","year":"2022","unstructured":"Shah RC, Hoyo V, Moussatche P, Volkov BB. Improving quality and efficiency of translational research: Environmental scan of adaptive capacity and preparedness of Clinical and Translational Science Award Program hubs. Journal of Clinical and Translational Science. 2022. https:\/\/doi.org\/10.1017\/CTS.2022.423.","journal-title":"Journal of Clinical and Translational Science"},{"issue":"10","key":"9677_CR88","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/S0277-9536(03)00060-1","volume":"57","author":"B Jentsch","year":"2003","unstructured":"Jentsch B, Pilley C. Research relationships between the South and the North: cinderella and the ugly sisters? Soc Sci Med. 2003;57(10):1957\u201367. https:\/\/doi.org\/10.1016\/S0277-9536(03)00060-1.","journal-title":"Soc Sci Med"},{"issue":"1","key":"9677_CR89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S12992-021-00731-2\/TABLES\/1","volume":"17","author":"JP Fanning","year":"2021","unstructured":"Fanning JP, Murthy S, Obonyo NG, et al. Global infectious disease research collaborations in crises: building capacity and inclusivity through cooperation. Global Health. 2021;17(1):1\u20136. https:\/\/doi.org\/10.1186\/S12992-021-00731-2\/TABLES\/1.","journal-title":"Global Health"},{"issue":"1","key":"9677_CR90","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/J.ANTIVIRAL.2007.10.008","volume":"78","author":"ES Higgs","year":"2008","unstructured":"Higgs ES, Hayden FG, Chotpitayasunondh T, Whitworth J, Farrar J. The Southeast Asian Influenza Clinical Research Network: development and challenges for a new multilateral research endeavor. Antivir Res. 2008;78(1):64\u20138. https:\/\/doi.org\/10.1016\/J.ANTIVIRAL.2007.10.008.","journal-title":"Antivir Res"},{"issue":"3","key":"9677_CR91","doi-asserted-by":"publisher","first-page":"520","DOI":"10.11124\/JBIES-22-00123","volume":"21","author":"D Pollock","year":"2023","unstructured":"Pollock D, Peters MDJ, Khalil H, et al. Recommendations for the extraction, analysis, and presentation of results in scoping reviews. JBI Evid Synth. 2023;21(3):520\u201332. https:\/\/doi.org\/10.11124\/JBIES-22-00123.","journal-title":"JBI Evid Synth"},{"issue":"4","key":"9677_CR92","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/JRSM.1123","volume":"5","author":"MT Pham","year":"2014","unstructured":"Pham MT, Raji\u0107 A, Greig JD, Sargeant JM, Papadopoulos A, Mcewen SA. A scoping review of scoping reviews: advancing the approach and enhancing the consistency. Res Synth Methods. 2014;5(4):371\u201385. https:\/\/doi.org\/10.1002\/JRSM.1123.","journal-title":"Res Synth Methods"},{"issue":"1","key":"9677_CR93","doi-asserted-by":"publisher","DOI":"10.1017\/CTS.2021.10","volume":"5","author":"BS Coller","year":"2021","unstructured":"Coller BS, Buse JB, Kimberly RP, Powderly WG, Zand MS. Re-engineering the clinical research enterprise in response to COVID-19: the clinical translational science award (CTSA) experience and proposed playbook for future pandemics. J Clin Transl Sci. 2021;5(1):e96. https:\/\/doi.org\/10.1017\/CTS.2021.10.","journal-title":"J Clin Transl Sci"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09677-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09677-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:42:12Z","timestamp":1779208932000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09677-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,7]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9677"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09677-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,7]]},"assertion":[{"value":"9 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}